In a study published in Pediatrics, researchers examined whether the United States’ public health recommendations encouraging early peanut introduction during infancy were associated with changes in real-world rates of food allergies among children. Using electronic health record data from a large, multi-state network of pediatric practices, the study compared allergy diagnoses before and after the pivotal 2015 and 2017 guideline releases.
shifting away from avoidance toward early exposure
Historically, pediatric guidance emphasized avoidance of common allergens and delayed introduction, particularly for children at elevated risk for atopic dermatitis or other allergic conditions. This avoidance paradigm began to waver in the last two decades as accumulating evidence suggested that delaying exposure does not reliably prevent allergies. The watershed LEAP trial in 2015 demonstrated that early, sustained peanut consumption in high-risk infants aged 4 to 11 months resulted in a substantial reduction in peanut allergy risk—approximately 81% in that high-risk group. Following LEAP, several health organizations issued updated pediatric guidelines advocating early introduction of allergenic foods, including peanuts.
Despite this shift, the real-world effectiveness of these guidelines—beyond controlled research settings—remained uncertain. Establishing whether early peanut exposure and related recommendations translate into fewer IgE-mediated food allergies in routine clinical practice could strengthen confidence in policy adoption and improve outcomes for millions of children.
About the study design
The study drew on data from the American Academy of Pediatrics Comparative Effectiveness Research through Collaborative Electronic Reporting (CER²) network, encompassing numerous US pediatric primary care practices. The researchers focused on children from birth to three years old and divided them into three cohorts based on entry timing into pediatric care and the observation period:
Preguidelines cohort: Entry between September 2012 and August 2014 with a 2-year observation window (n = 38,594)
Postguidelines cohort: Entry between September 2015 and August 2017 (after the 2015 guidelines) with a 2-year observation window (n = 46,680)
Post-addendum guidelines cohort: Entry between February 2017 and January 2019 (after the 2017 addendum with more specific dietary guidance) with a 1-year observation window (n = 39,594)
The primary outcome was cumulative incidence of immunoglobulin E-mediated food allergy (IgE-FA), the most common type of food allergy identified in these periods. The researchers employed several analytic approaches:
- Univariable logistic regression to compare allergy frequencies across subgroups
- Cox proportional hazards modeling to estimate allergy risk before and after guidelines
- Interrupted time series (ITS) analysis to evaluate policy impact on IgE-FA–associated outcomes
- Key findings: reductions in peanut and overall IgE-FA after guidelines
The analysis revealed a significant association between guideline publication and a lower frequency of IgE-FA–related food allergies. When comparing the pre-guidelines cohort to the post-addendum guidelines cohort within the 1-year observation window, the cumulative incidence of peanut IgE-FA declined from 0.79% to 0.45%, corresponding to roughly a 45% reduction in the hazard of diagnosis (Hazard Ratio [HR] 0.55, p < 0.0001).
Beyond peanuts, the reduction extended to overall IgE-mediated allergies. Across all investigated allergies, the cumulative incidence dropped from 1.46% in the pre-guidelines period to 0.93% in the post-addendum period, equating to about a 37% decrease in risk (HR 0.63, p < 0.0001).
Notably, the study observed differing effects in subgroups and across allergen types. Among children with prior atopic dermatitis—a high-risk group—the data did not show a significant reduction in peanut allergy risk. The incidence of cow’s milk allergy declined, while egg allergy did not show a similar decline. Interestingly, as peanut allergies decreased, egg allergy became the more prevalent allergen in the post-guideline cohorts.
Concurrent trends also emerged. The incidence of atopic dermatitis, a known risk factor for developing food allergies, rose during the study period (p < 0.0001), which may reflect earlier recognition and diagnosis by pediatricians. Demographic shifts were observed as well: fewer Black, Asian/Pacific Islander, and Hispanic children were represented among those diagnosed with food allergies in the post-guideline periods.
The ITS analysis confirmed a significant decline in any food allergy diagnoses but did not reach statistical significance for peanut allergy alone, highlighting the complexity of disentangling guideline effects on specific allergens in real-world data.
Conclusions
This study represents a robust, real-world examination of the potential publ
ic health benefits of the United States’ shift toward early introduction of allergenic foods. The findings suggest that the 2015 and 2017 guidelines were followed by a measurable association with reduced new diagnoses of peanut and overall IgE-mediated food allergies in US infants.
However, the authors emphasize that the observed associations do not prove causation. The reductions were more modest than the dramatic results seen in the controlled LEAP trial, indicating opportunities to strengthen implementation and adherence in everyday practice. The study period concluded before assessing potential impacts from newer guidelines issued after 2021.
Overall, the research supports the premise that early introduction guidelines can contribute to a healthier, less allergy-prone pediatric population, while also underscoring the need for ongoing surveillance and targeted efforts to optimize guideline adoption and effectiveness across diverse populations.
Related topics
